RecruitingNCT01731665
Epidemiology of Inflammatory Bowel Disease in the Songpa-Kangdong District, Seoul, Korea.
Sponsor
Asan Medical Center
Enrollment
2,000 participants
Start Date
Dec 1, 2012
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this study is to evaluate the incidence, prevalence, clinical characteristics and prognosis of Crohn's disease and ulcerative colitis over time in a district of Seoul, Korea.
Eligibility
Plain Language Summary
Simplified for easier understanding
This study tracks the number of people diagnosed with inflammatory bowel disease (IBD) — specifically Crohn's disease and ulcerative colitis — in a specific district of Seoul, South Korea, to understand how common these conditions are becoming.
**You may be eligible if...**
- You have been definitively diagnosed with Crohn's disease or ulcerative colitis based on standard medical criteria (symptoms, imaging, biopsies, and scope exams)
- You are of Korean ethnicity living in the Songpa-Kangdong district of Seoul
**You may NOT be eligible if...**
- Your IBD cannot be classified as either Crohn's disease or ulcerative colitis
- You are not of Korean ethnic background
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT01731665
Related Trials
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
NCT0381634552 locations
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting
NCT06581328101 locations
Study to Assess Change in Disease Activity of Risankizumab Treatment in Adult Participants With Moderate to Severe Ulcerative Colitis
NCT0676470656 locations
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
NCT07186101149 locations
Immune Regulation in Ulcerative Colitis or Crohn s Disease
NCT000011841 location